Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMOR-1 for Hypocalcemia in Hypoparathyroidism
NCT06547151Phase 2Active, not recruiting
- Sponsor
- Amorphical
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amorphous calcium carbonate in hypoparathyroidism (2 arms), sponsored by Amorphical. Primary endpoint: Percentage of Subjects Who Achieved the Primary Composite Endpoint at 14 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
amorphous calcium carbonate
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT06547151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547151.